MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets

被引:270
作者
Siddiqui, Ohidul [1 ]
Hung, H. M. James [1 ]
O'Neill, Robert [1 ]
机构
[1] US FDA, Off Biostat, Off Translat Sci, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
关键词
Ignorable missing data; Last observation carried forward; Missing at random; Missing completely at random; Missing not at random; LONGITUDINAL CLINICAL-TRIALS; PATTERN-MIXTURE MODELS; MISSING DATA; DROP-OUT; INCOMPLETE DATA;
D O I
10.1080/10543400802609797
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
In recent years, the use of the last observation carried forward (LOCF) approach in imputing missing data in clinical trials has been greatly criticized, and several likelihood-based modeling approaches are proposed to analyze such incomplete data. One of the proposed likelihood-based methods is the Mixed-Effect Model Repeated Measure (MMRM) model. To compare the performance of LOCF and MMRM approaches in analyzing incomplete data, two extensive simulation studies are conducted, and the empirical bias and Type I error rates associated with estimators and tests of treatment effects under three missing data paradigms are evaluated. The simulation studies demonstrate that LOCF analysis can lead to substantial biases in estimators of treatment effects and can greatly inflate Type I error rates of the statistical tests, whereas MMRM analysis on the available data leads to estimators with comparatively small bias, and controls Type I error rates at a nominal level in the presence of missing completely at random (MCAR) or missing at random (MAR) and some possibility of missing not at random (MNAR) data. In a sensitivity analysis of 48 clinical trial datasets obtained from 25 New Drug Applications (NDA) submissions of neurological and psychiatric drug products, MMRM analysis appears to be a superior approach in controlling Type I error rates and minimizing biases, as compared to LOCF ANCOVA analysis. In the exploratory analyses of the datasets, no clear evidence of the presence of MNAR missingness is found.
引用
收藏
页码:227 / 246
页数:20
相关论文
共 28 条
[1]
The impact of missing data and how it is handled on the rate of false-positive results in drug development [J].
Barnes, Sunni A. ;
Mallinckrodt, Craig H. ;
Lindborg, Stacy R. ;
Carter, M. Kallin .
PHARMACEUTICAL STATISTICS, 2008, 7 (03) :215-225
[2]
Last observation carry-forward and last observation analysis [J].
Carpenter, J ;
Kenward, M ;
Evans, S ;
White, I .
STATISTICS IN MEDICINE, 2004, 23 (20) :3241-3242
[3]
Marginal analysis of incomplete longitudinal binary data: A cautionary note on LOCF imputation [J].
Cook, RJ ;
Zeng, LL ;
Yi, GY .
BIOMETRICS, 2004, 60 (03) :820-828
[4]
DIGGLE P, 1994, APPL STAT-J ROY ST C, V43, P49
[5]
Fitzmaurice G., 2004, Applied longitudinal analysis
[6]
STATISTICAL HANDLING OF DROP-OUTS IN LONGITUDINAL CLINICAL-TRIALS [J].
HEYTING, A ;
TOLBOOM, JTBM ;
ESSERS, JGA .
STATISTICS IN MEDICINE, 1992, 11 (16) :2043-2061
[7]
Hogan JW, 1997, STAT MED, V16, P259
[8]
MISSING DATA IN LONGITUDINAL-STUDIES [J].
LAIRD, NM .
STATISTICS IN MEDICINE, 1988, 7 (1-2) :305-315
[9]
RANDOM-EFFECTS MODELS FOR LONGITUDINAL DATA [J].
LAIRD, NM ;
WARE, JH .
BIOMETRICS, 1982, 38 (04) :963-974
[10]
Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches [J].
Lane, Peter .
PHARMACEUTICAL STATISTICS, 2008, 7 (02) :93-106